Latest Platform Technology News

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

hipages Group has acquired a majority stake in VIZ Insurance, marking its strategic entry into the insurance sector for tradies and broadening its platform offerings.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Netwealth delivered a resilient March quarter with $4 billion in net inflows, pushing total funds under administration to $125.8 billion despite a 3.7% market dip. Growth in Managed Accounts and new intermediary relationships underpin ongoing momentum.

Metallium Limited has completed Phase I of a U.S. Department of War SBIR contract, demonstrating its Flash Joule Heating technology can recover gallium from semiconductor and electronic waste. The program finished in six months, underscoring the technology’s readiness and aligning with U.S. strategic supply chain goals.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Firebird Metals has locked in exclusive global rights to five critical LMFP patents, solidifying its position in the lithium-ion battery materials market and paving the way for its Australian Demonstration Plant.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

EPX Limited has successfully raised nearly $295,000 through a Security Purchase Plan, supporting its recent acquisition of Wattwatchers and positioning the company for further expansion.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.